Background: Abiraterone acetate and enzalutamide both improve outcomes in patients with metastatic castrationresistant prostate cancer (mCRPC). Optimal sequencing for these agents and whether cross-resistance occurs is unknown.
introduction
Prostate cancer is the most common cancer among men, and the second leading cause of male cancer death in the Western world [1] . Since 2010, five new agents have demonstrated survival benefit in metastatic castration-resistant prostate cancer, including radium-223 dichloride, sipuleucel-T, cabazitaxel, abiraterone acetate, and enzalutamide [2] [3] [4] [5] [6] . This rapid development has created a clinical dilemma with respect to the optimal sequencing of treatments.
Two of these new agents focus on novel ways to suppress androgen receptor (AR) signalling. Abiraterone acetate does so by inhibiting the enzyme CYP17A1, thereby affecting two critical steps in the synthesis of androgens from precursors and suppressing extragonadal androgen production [7] . Enzalutamide, on the other hand, is a next-generation antiandrogen that binds to the AR with high affinity and prevents ligand-dependent activation and receptor translocation to the nucleus, without agonistic activity [8] . Although they both target persistent AR signalling, given the mechanistic differences, we postulated that patients with disease progression on one of these agents may respond to subsequent treatment with the other. However, it is also possible that mechanisms of resistance to one agent may lead to cross-resistance to the other, such as through the emergence of AR variants or ligand binding domain mutations or noncanonical AR-based signalling through oncogenic kinases [9] [10] [11] . To evaluate this, we reviewed the outcomes of patients treated with enzalutamide and, upon disease progression, were subsequently treated with abiraterone acetate. methods Canada; Cross Cancer Institute, Edmonton, AB, Canada; and Duke Cancer Institute, Duke University, North Carolina, USA. Eligible subjects included men with metastatic castration-resistant prostate cancer (CRPC) enrolled in the AFFIRM trial [5] and randomized to the enzalutamide arm; progressed on enzalutamide; and then received at least one dose of abiraterone acetate. A total of 30 patients were identified.
Medical records were reviewed for patient demographics, disease characteristics, prior treatments and duration of treatment, both at the time of enzalutamide and abiraterone initiation; response to treatments, including radiographic, prostate-specific antigen (PSA), and symptomatic; and adverse events. Research ethics board approval was obtained at all sites. All data transferred from the other centres was in a de-identified format.
Progression-free survival (PFS) was defined as time from start of abiraterone to time of PSA progression (PSA increase of 25% from nadir and a minimum of 2 ng/ml), radiographic progression, and/or symptomatic progression. Prostate Cancer Working Group 2 criteria were not mandated as these patients were not treated in the clinical trial setting. Overall survival (OS) was defined from the time of abiraterone start to date of death from any cause. Survival was estimated by the method of Kaplan and Meier. To be evaluable for response to abiraterone, at least one followup visit and PSA measurement were required after abiraterone initiation. Waterfall plots were used to illustrate best PSA response to enzalutamide and abiraterone. As the primary outcome measure, proportions were used to analyse the percentage of patients who had a ≥30% PSA decline on abiraterone and enzalutamide. For response rates, exact binomial 95% confidence intervals were calculated. Exploratory, univariate analyses of the effects of baseline characteristics, and prior treatments on abiraterone response and survival were also performed using Cox-proportional hazards modelling. A comparison was performed of patient demographics, laboratory values, disease characteristics, and prior treatments at enzalutamide and abiraterone initiation. Chi-square tests or Fisher's exact tests were used for categorical variables, and Student's t-tests were used for ordinal variables.
results
Thirty patients who received abiraterone after progressing on enzalutamide were available for analysis. Twenty-seven patients were evaluable for efficacy analysis, as three patients had no follow-up information. The patient characteristics at the time of enzalutamide and abiraterone acetate initiation are summarized in Table 1 . The median age was 70 years (range 56-84 years). At the time of enzalutamide initiation 86% of patients had an ECOG performance status of 0 or 1, while this trended to a lower value at the time of abiraterone initiation (70%) (P = 0.652). At abiraterone initiation, more patients required opiate analgesics (53% versus 36%, P < 0.005) compared with enzalutamide initiation. With respect to laboratory data, the median haemoglobin was 123 g/l at enzalutamide initiation and 116 g/l at abiraterone initiation (P = 0.454). Alkaline phosphatase and lactate dehydrogenase were elevated in 27% of patients at enzalutamide initiation, and in 40% (P < 0.005) and 20% (P = 0.020), respectively, at abiraterone initiation. At the time of enzalutamide initiation, 80%, 60%, and 27% of patients had bone, nodal, and visceral metastases, respectively. A non-statistically higher proportion of patients had bone, and visceral metastases at abiraterone initiation (87% and 30%, respectively), while the proportion of patients with nodal metastases were similar (60%). Table 1 provides a summary of previous treatments prior to enzalutamide and post-enzalutamide but prior to abiraterone. Prior to treatment with enzalutamide, 63% of patients had received palliative radiotherapy, while post-enzalutamide 23% of patients were treated with palliative radiotherapy (P = 0.618). All patients had received prior anti-androgens including bicalutamide (86%), flutamide (23%) and nilutamide (13%). Seven percent of patients had received prior ketoconazole; all were given before enzalutamide initiation. All patients received docetaxel before enzalutamide (median 10 cycles, range 3-18), while five patients were re-treated with docetaxel following enzalutamide (median 3 cycles, range 1-8), but before abiraterone. One patient was given mitoxantrone pre-enzalutamide and one pre-abiraterone. Two patients received sipuleucel-T after progressing on enzalutamide. Treatment duration with enzalutamide was for a median of 41 weeks (range 6-95 weeks). Reasons for discontinuation of enzalutamide included progression of disease (80%), withdrawal of consent (10%), and toxicity (10%). Toxicities resulting in discontinuation of enzalutamide occurred in three patients. One patient discontinued enzalutamide due to nausea, one due to fatigue, and one due to seizure. The median duration of abiraterone treatment was 13 weeks (range 1-52 weeks) (P < 0.005). All abiraterone treatment discontinuations were due to disease progression. Of the 25 patients who progressed on abiraterone, 63% were PSA, 30% were symptomatic, and 52% were measurable progressions. No patients stopped abiraterone due to toxicity, and no dosereductions were required.
treatments administered

PSA decline
Twenty-seven of 30 patients were evaluable for best PSA response to abiraterone after progressing on enzalutamide. Three patients were excluded from the analysis as they had insufficient follow-up. Waterfall plots of best decrease in PSA expressed as a percentage from baseline per patient while on enzalutamide and abiraterone are shown in Figure 1 . Overall 23%, 60%, and 70% of patients achieved at least a 90%, 50%, and 30% decline in PSA as best response on enzalutamide. In contrast, 0%, 3%, and 11% of patients achieved at least a 90%, 50%, and 30% decline in PSA as best response on subsequent abiraterone. The median percent change in PSA in patients on enzalutamide was a 67% decline, while on abiraterone the median percent change was an increase of 18%. Of the three patients who had an at least 30% decline in PSA on abiraterone, one patient continues to respond to abiraterone at 29 weeks of follow-up, while the other two patients had time to PSA progression of 18 and 21 weeks. Of the 21 patients with a ≥30% PSA decline on enzalutamide, only one (5%) had a >30% PSA decline on subsequent abiraterone. Of the nine patients with a <30% PSA decline or PSA increase on enzalutamide, two (22%) had a >30% PSA decline on abiraterone. Specifically, these two patients had PSA increases of 8% and 15% on enzalutamide yet 55% and 48% PSA declines on abiraterone, respectively. (Figure 2a and b ). An exploratory univariate analysis was performed to evaluate the effects of age (≤70, >70 years), pain, increased lactate dehydrogenase, increased alkaline phosphatase, anaemia, location of metastases (visceral versus non-visceral), and prior enzalutamide PFS (≤40 weeks versus >40 weeks) on the PFS with abiraterone (Table 2) . Only age >70 years was associated with a worse PFS [median PFS of 14.6 weeks (95% CI 7.6-21.5) versus 18 weeks (95% CI 7.4-28.6) for patients ≤70 years (P = 0.041)].
Patients with a PSA decline as best response on abiraterone had a longer PFS (median PFS of 28.1 weeks (95% CI 19.8-36.5) than those who did not have a PSA decline on abiraterone [median PFS of 12.5 (95% CI 7.5-16.8) (P = 0.002)]. OS in patients with any PSA decline on abiraterone was 48.7 weeks (95% CI 16.0-81.4) versus 50.1 weeks to those patients without a PSA decline on abiraterone (95% CI 10.8-89.5) (P = 0.48).
discussion
In this retrospective study of patients previously treated with docetaxel and enzalutamide, the response rate and survival outcomes with subsequent abiraterone acetate treatment were modest. While 70% of patients had a ≥30% PSA decline on enzalutamide, only 11% of patients had a PSA decline of at least 30% on subsequent abiraterone acetate and prednisone. The median duration of treatment and PFS on abiraterone acetate was brief at 16.8 weeks (95% CI 12.4-21.3) and 15.4 weeks (95% CI 10.7-20.2), respectively. This compares unfavourably with the published data on abiraterone acetate in the post-docetaxel metastatic CRPC setting [12] , in which PFS using a variety of definitions ranged from 22.4 to 34 weeks. Although this suggests cross-resistance between the two agents, the men in the current analysis were further along in their disease course with greater tumour burden, more symptoms, and more adverse prognostic features than those in the phase III trial given that their disease had also progressed following enzalutamide. Thus, these negative prognostic features are a further contributing factor to the poor outcomes observed in these patients. Therapy with abiraterone acetate in this advanced group of patients appeared to be well-tolerated with no treatment discontinuations or dose reductions for toxicity. These data are consistent with Bianchini and coworkers who have also recently noted similar findings in a study that examined the response of 39 patients receiving abiraterone acetate after progressing on enzalutamide. Eight percent (5 of 24) of patients had a ≥50% decline in PSA with abiraterone acetate and median PFS in their cohort was 2.7 months (95% CI 2.2-3.9) [13] .
While enzalutamide and abiraterone acetate have different mechanisms of action by either inhibiting the AR directly or by inhibiting extragonadal androgen synthesis, both target persistent AR signalling, and these data suggest that an element of clinical cross-resistance may develop between the two therapies. Interestingly, of the three patients with a ≥30% PSA decline on abiraterone, two of these patients had either original articles Annals of Oncology stable disease or progression as best response to prior enzalutamide, indicating that primary insensitivity to enzalutamide may not preclude response to abiraterone acetate.
This data highlights the heterogeneity of prostate cancers with respect to AR signalling addiction and mechanisms of resistance. Potential resistance mechanisms to enzalutamide include AR amplification, AR splice, or deletion variants where the AR remains constitutively active, mutation of the ligand binding site, and cross-talk between AR and growth factor and oncogenic kinase pathways [9] [10] [11] [14] [15] . Many of these mechanisms would also be expected to result in resistance to abiraterone acetate's effect on ligand production. Recent in vitro data suggests that abiraterone may also have direct AR antagonistic effects [16] , providing further mechanistic rationale for the responses observed in this study to secondline treatment with abiraterone acetate. Our data highlight the need for novel combination studies and novel agents targeting a range of pathogenic mechanisms in CRPC, given the relatively short period of treatment benefit with the sequential use of these hormonal agents.
Our study has several important limitations: it is a small retrospective study subject to selection bias, incomplete information, and variable assessment intervals during treatment with abiraterone acetate. Our primary outcome measure of activity was PSA decline; however, as mCRPC progresses, there may be dedifferentiation of tumour cells [17] . Therefore, PSA may not be an accurate reflection of disease response and progression. Moreover, further targeting AR 
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signalling may not be the correct strategy. Ongoing efforts to determine the biologic basis of progression by profiling tissues of patients after therapy or at the time of resistance to abiraterone acetate and/or enzalutamide will help to guide future treatment directions.
conclusion
In this study, patients who previously progressed on enzalutamide had a modest response rate and brief duration of effect to subsequent treatment with abiraterone. However, there was a small subset of patients with PSA progression as best response to enzalutamide, who subsequently responded to abiraterone. This highlights the heterogeneity of prostate cancer and the importance of delineating predictive biomarkers markers to help in selection of therapy. The clinical activity of enzalutamide after progression on abiraterone and vice versa should be evaluated in a prospective manner to assist in the determination of the optimal sequencing of these agents. 
